Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi-aventis farmacÊutica ltda - sulfato de hidroxicloroquina - antimalaricos

União Europeia - português - EMA (European Medicines Agency)

alfasigma s.p.a. - piperaquine tetraphosphate, artenimol - malária - antiprotozoários - eurartesim é indicado para o tratamento da malária de plasmodium falciparum sem complicações em adultos, crianças e lactentes com 6 meses e mais e pesa 5 kg ou mais. deve ser tido em consideração a orientação oficial sobre o uso apropriado de agentes.

União Europeia - português - EMA (European Medicines Agency)

roche registration gmbh - saquinavir - infecções por hiv - antivirais para uso sistêmico - invirase é indicado para o tratamento de pacientes adultos infectados com hiv-1. invirase só deve ser administrada em combinação com ritonavir e outros medicamentos anti-retrovirais.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

alfasigma portugal, lda - hidroxicloroquina - comprimido - 400 mg - hidroxicloroquina, sulfato 400 mg - hydroxychloroquine - n/a - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

alfasigma portugal, lda - hidroxicloroquina - comprimido - 400 mg - hidroxicloroquina, sulfato 400 mg - hydroxychloroquine - n/a - duração do tratamento: longa duração

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

cristÁlia produtos quÍmicos farmacÊuticos ltda. - saquinavir - antiviroticos (inibe replicacao virotica)

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi medley farmacÊutica ltda. - sulfato de hidroxicloroquina - antimalaricos

União Europeia - português - EMA (European Medicines Agency)

mylan ireland limited - lenalidomida - mieloma múltiplo - imunossupressores - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

União Europeia - português - EMA (European Medicines Agency)

mylan ireland limited - acetato de abiraterona - neoplasias prostáticas - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

União Europeia - português - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas em diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.